WO2002056900A3 - Verwendung von slpi zur behandlung chronisch-entzündlicher darmerkrankungen - Google Patents

Verwendung von slpi zur behandlung chronisch-entzündlicher darmerkrankungen Download PDF

Info

Publication number
WO2002056900A3
WO2002056900A3 PCT/EP2001/014518 EP0114518W WO02056900A3 WO 2002056900 A3 WO2002056900 A3 WO 2002056900A3 EP 0114518 W EP0114518 W EP 0114518W WO 02056900 A3 WO02056900 A3 WO 02056900A3
Authority
WO
WIPO (PCT)
Prior art keywords
slpi
chronic inflammatory
intestinal diseases
inflammatory intestinal
treating chronic
Prior art date
Application number
PCT/EP2001/014518
Other languages
English (en)
French (fr)
Other versions
WO2002056900A2 (de
Inventor
Manfred Nilius
Original Assignee
Manfred Nilius
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Manfred Nilius filed Critical Manfred Nilius
Priority to EP01985389A priority Critical patent/EP1353680A2/de
Priority to JP2002557407A priority patent/JP2004520362A/ja
Priority to US10/250,901 priority patent/US20040106564A1/en
Publication of WO2002056900A2 publication Critical patent/WO2002056900A2/de
Publication of WO2002056900A3 publication Critical patent/WO2002056900A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Die vorliegende Erfindung betrifft die Verwendung von sekretorischem Leukocyten-Protease-Inhibitor (SLPI) oder eines zur SLPI-Bildung befähigten nicht-pathogenen Mikroorganismus, der eine SLPI codierende Nucleinsäure enthält, zur herstellung eines medikamentes zur Behandlung chronisch-entzündlicher Darmerkrankungen von Mensch und Tier, pharmazeutische Zusammensetzungen zur oralen oder rektalen Verabreichung, die den Wirkstoff SLPI oder SLPI-exprimierende Mikroorganismen enthalten, sowie Verfahren zur Herstellung dieser pharmazeutischen Zusammensetzungen.
PCT/EP2001/014518 2001-01-17 2001-12-11 Verwendung von slpi zur behandlung chronisch-entzündlicher darmerkrankungen WO2002056900A2 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP01985389A EP1353680A2 (de) 2001-01-17 2001-12-11 Verwendung von slpi zur behandlung chronisch-entzündlicher darmerkrankungen
JP2002557407A JP2004520362A (ja) 2001-01-17 2001-12-11 慢性炎症性腸疾患の治療のためのｓｌｐｉの使用
US10/250,901 US20040106564A1 (en) 2001-01-17 2001-12-11 Use of slpi for treating chronic inflammatory intestinal diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10101793A DE10101793A1 (de) 2001-01-17 2001-01-17 Verwendung von SLPI zur Behandlung chronisch-entzündlicher Darmerkrankungen
DE10101793.6 2001-01-17

Publications (2)

Publication Number Publication Date
WO2002056900A2 WO2002056900A2 (de) 2002-07-25
WO2002056900A3 true WO2002056900A3 (de) 2003-04-24

Family

ID=7670741

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/014518 WO2002056900A2 (de) 2001-01-17 2001-12-11 Verwendung von slpi zur behandlung chronisch-entzündlicher darmerkrankungen

Country Status (5)

Country Link
US (1) US20040106564A1 (de)
EP (1) EP1353680A2 (de)
JP (1) JP2004520362A (de)
DE (1) DE10101793A1 (de)
WO (1) WO2002056900A2 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107002090B (zh) * 2014-05-01 2021-09-10 阿苏萨医药科学有限公司 异源多肽表达盒

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050064447A1 (en) * 2001-04-18 2005-03-24 Sheng-He Huang Probiotic therapy of neonatal meningitis and method of using E. coli virulence determinatns
CA2554683C (en) * 2004-02-04 2014-06-10 Pharmaaware Sepsis B.V. Use of alkaline phosphatase for the detoxification of lps present at mucosal barriers
DK1964570T3 (da) 2007-03-02 2012-12-17 Protectimmun Gmbh Farmaceutisk sammensætning til beskyttelse mod allergier og inflammatoriske sygdomme
DE202007003266U1 (de) 2007-03-02 2008-07-17 Bufe, Albrecht, Prof. Dr. Med. Pharmazeutische Zusammensetzung zum Schutz vor Allergien und entzündlichen Erkrankungen
US20120128597A1 (en) 2008-08-16 2012-05-24 Forschungszentrum Borstel Composition for prevention and treatment of allergic and/or inflammatory diseases
CA2764321A1 (en) * 2009-06-03 2010-12-09 Ondek Pty Ltd Novel strains of helicobacter pylori and uses thereof
EP2451467B1 (de) 2010-01-14 2016-12-21 INSERM - Institut National de la Santé et de la Recherche Médicale Rekombinante probiotische bakterien zur vorbeugung und behandlung der chronisch-entzündlichen darmerkrankung und des reizdarmsyndroms
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
EP2706067A1 (de) * 2012-09-06 2014-03-12 Humboldt-Universität zu Berlin Probiotische Bakterie als Träger für einen aus Enthelminthen stammenden Immunmodulator zur Behandlung von entzündlichen Krankheiten
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
DK3461891T3 (da) 2014-01-24 2020-08-10 Am-Pharma Bv Nedstrømsbehandling af en alkalisk phosphatase
PE20161442A1 (es) 2014-01-24 2017-01-12 Am-Pharma B V Proteinas quimericas tipo fosfatasa alcalina
MX2017008449A (es) 2014-12-23 2017-10-12 4D Pharma Res Ltd Polipeptido de pirina y modulacion inmune.
CN113862175A (zh) 2014-12-23 2021-12-31 4D制药研究有限公司 免疫调控
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
AU2016278067B2 (en) 2015-06-15 2022-09-22 Cj Bioscience, Inc. Compositions comprising bacterial strains
CA2988695A1 (en) 2015-06-15 2016-12-22 4D Pharma Research Limited Compositions comprising bacterial strains
CN114984057A (zh) 2015-06-15 2022-09-02 4D制药研究有限公司 包含细菌菌株的组合物
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
PT3209310T (pt) 2015-11-20 2018-04-20 4D Pharma Res Ltd Composições compreendendo estirpes bacterianas
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
CA3016179C (en) 2016-03-04 2019-08-13 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
PL3630136T3 (pl) 2017-05-22 2021-09-13 4D Pharma Research Limited Kompozycje zawierające szczepy bakteryjne
WO2018215782A1 (en) 2017-05-24 2018-11-29 4D Pharma Research Limited Compositions comprising bacterial strain
WO2018229188A1 (en) 2017-06-14 2018-12-20 4D Pharma Research Limited Compositions comprising bacterial strains
DK3600364T3 (da) 2017-06-14 2020-08-31 4D Pharma Res Ltd Sammensætninger omfattende en bakteriestamme af slægten megasphaera og anvendelser deraf
WO2020231930A1 (en) * 2019-05-11 2020-11-19 The Texas A&M University System Protein inhibitors of clostridium difficile toxin b

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633227A (en) * 1994-09-12 1997-05-27 Miles, Inc. Secretory leukocyte protease inhibitor as an inhibitor of tryptase
WO2000044390A1 (en) * 1999-02-01 2000-08-03 John Lezdey Treatment of bladder and gastrointestinal mastocytosis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633227A (en) * 1994-09-12 1997-05-27 Miles, Inc. Secretory leukocyte protease inhibitor as an inhibitor of tryptase
WO2000044390A1 (en) * 1999-02-01 2000-08-03 John Lezdey Treatment of bladder and gastrointestinal mastocytosis

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BERGENFELDT M ET AL: "LOCALIZATION OF IMMUNOREACTIVE SECRETORY LEUKOCYTE PROTEASE INHIBITOR (SLPI) IN INTESTINAL MUCOSA", JOURNAL OF GASTROENTEROLOGY, SPRINGER VERLAG, TOKYO, JP, vol. 1, no. 31, February 1996 (1996-02-01), pages 18 - 23, XP001079268, ISSN: 1340-9077 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; February 1999 (1999-02-01), BLAUKAT ANDREE ET AL: "Effects of gene dosage on the expression of a functionally active C-terminal domain of human mucus proteinase inhibitor in E. coli.", XP002208406, Database accession no. PREV199900203801 *
MELANI LORENZO ET AL: "Antiinflammatory effects of secretory leuko-proteinase inhibitor (SLPI) in rabbit immune colitis.", GASTROENTEROLOGY, vol. 110, no. 4 SUPPL., 1996, 96th Annual Meeting of the American Gastroenterological Association and the Digestive Disease Week;San Francisco, California, USA; May 19-22, 1996, pages A966, XP001094369, ISSN: 0016-5085 *
PROTEIN AND PEPTIDE LETTERS, vol. 6, no. 1, February 1999 (1999-02-01), pages 35 - 41, ISSN: 0929-8665 *
SI-TAHAR M ET AL: "Constitutive and regulated secretion of secretory leukocyte proteinase inhibitor by human intestinal epithelial cells.", GASTROENTEROLOGY. UNITED STATES JUN 2000, vol. 118, no. 6, June 2000 (2000-06-01), pages 1061 - 1071, XP002208403, ISSN: 0016-5085 *
STEIDLER L ET AL: "Treatment of murine colitis by Lactococcus lactis secreting interleukin-10.", SCIENCE. UNITED STATES 25 AUG 2000, vol. 289, no. 5483, 25 August 2000 (2000-08-25), pages 1352 - 1355, XP002208404, ISSN: 0036-8075 *
STETLER G L ET AL: "SECRETION OF ACTIVE, FULL- AND HALF-LENGTH HUMAN SECRETORY LEUKOCYTE PROTEASE INHIBITOR BY SACCHAROMYCES CEREVISIAE", BIO/TECHNOLOGY, NATURE PUBLISHING CO. NEW YORK, US, vol. 7, no. 1, 1989, pages 55 - 60, XP000023504, ISSN: 0733-222X *
WHALEY K J ET AL: "Transgenic commensals as mucosal protectants.", NATURE BIOTECHNOLOGY. UNITED STATES OCT 2000, vol. 18, no. 10, October 2000 (2000-10-01), pages 1038 - 1039, XP002208405, ISSN: 1087-0156 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107002090B (zh) * 2014-05-01 2021-09-10 阿苏萨医药科学有限公司 异源多肽表达盒

Also Published As

Publication number Publication date
DE10101793A1 (de) 2002-08-01
JP2004520362A (ja) 2004-07-08
EP1353680A2 (de) 2003-10-22
US20040106564A1 (en) 2004-06-03
WO2002056900A2 (de) 2002-07-25

Similar Documents

Publication Publication Date Title
WO2002056900A3 (de) Verwendung von slpi zur behandlung chronisch-entzündlicher darmerkrankungen
IL157656A (en) Metalloproteinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for the treatment of diseases mediated by metalloproteinase enzymes
WO2004055006A8 (en) Novel compounds having selective inhibiting effect at gsk3
WO2004006858A3 (en) Compounds, compositions, and methods employing same
WO2002017914A8 (en) Fused pyrrolocarbazoles against inflammation
HUP0301246A2 (hu) Humán véralvadási faktor VII változatai
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
WO2003082853A8 (en) New compounds
WO2001076370A3 (en) Anthelmintic combinations
EP1830191A3 (de) Pharmazeutische Erzeugnisse, enthaltend Thiazolidindionen zur Behandlung von endokrinen Autoimmunerkrankungen
ZA200303037B (en) Herbal pharmaceutical composition for treatment of HIV/Aids patients.
WO2002088100A3 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
WO2005063764A3 (en) Fused pyrrolocarbazoles and methods for the preparation thereof
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
WO2005004906A3 (de) Verwendung von dp iv- und apn inhibitoren zur behandlung dermatologischer erkrankungen mit hyperproliferation und veränderten differenzierungszuständen von fibroblasten
WO2003050067A3 (fr) Analogues de la vitamine d
WO2003018535A3 (en) Novel aminobenzoephenones
WO2002070741A3 (en) Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the dna
WO2002059327A3 (en) Sulfatases and methods of use thereof
GB0228552D0 (en) Chemical compounds
WO2003024996A3 (de) Antibakterielle makrozyklen
WO2001051489A3 (en) Methods for lowering uric acid levels
WO2002074034A3 (de) Neue arzneimittelkompositionen auf der basis von anticholinergika und endothelinantagonisten
WO2002072098A8 (en) Method of treatment
WO2004030684A3 (en) Kavalactone product

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2001985389

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002557407

Country of ref document: JP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2001985389

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10250901

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2001985389

Country of ref document: EP